Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Depressive Disorder, Major | 7 | 2021 | 852 | 0.84 | Why? |
| Corticotropin-Releasing Hormone | 1 | 2017 | 15 | 0.73 | Why? |
| Quinidine | 1 | 2017 | 7 | 0.71 | Why? |
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2017 | 14 | 0.71 | Why? |
| Dextromethorphan | 1 | 2017 | 6 | 0.70 | Why? |
| Depressive Disorder, Treatment-Resistant | 1 | 2017 | 99 | 0.61 | Why? |
| Stress Disorders, Post-Traumatic | 7 | 2021 | 2963 | 0.60 | Why? |
| Antidepressive Agents | 1 | 2017 | 509 | 0.46 | Why? |
| Burnout, Professional | 4 | 2021 | 2489 | 0.43 | Why? |
| Resilience, Psychological | 2 | 2020 | 2329 | 0.37 | Why? |
| Neurosciences | 1 | 2009 | 148 | 0.33 | Why? |
| Health Personnel | 7 | 2021 | 29646 | 0.33 | Why? |
| Molecular Biology | 1 | 2009 | 139 | 0.32 | Why? |
| Occupational Stress | 1 | 2020 | 2044 | 0.31 | Why? |
| Hippocampus | 1 | 2008 | 237 | 0.31 | Why? |
| Neuropeptide Y | 2 | 2018 | 14 | 0.30 | Why? |
| New York City | 9 | 2021 | 7432 | 0.30 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.26 | Why? |
| Catecholamines | 1 | 2002 | 66 | 0.24 | Why? |
| Irritable Mood | 1 | 2021 | 93 | 0.22 | Why? |
| Serotonin | 1 | 2002 | 137 | 0.22 | Why? |
| Mental Disorders | 2 | 2021 | 6742 | 0.21 | Why? |
| Receptors, GABA-A | 1 | 2018 | 15 | 0.19 | Why? |
| Anxiety Disorders | 4 | 2021 | 2290 | 0.19 | Why? |
| Receptors, Corticotropin-Releasing Hormone | 1 | 2017 | 5 | 0.19 | Why? |
| Hospitals, Urban | 2 | 2021 | 950 | 0.18 | Why? |
| Stress, Psychological | 5 | 2021 | 10231 | 0.17 | Why? |
| Personnel, Hospital | 2 | 2021 | 2273 | 0.17 | Why? |
| Adaptation, Psychological | 2 | 2020 | 4996 | 0.17 | Why? |
| Mental Health | 2 | 2020 | 15770 | 0.16 | Why? |
| Cerebral Cortex | 1 | 2018 | 276 | 0.15 | Why? |
| Neuroprotective Agents | 1 | 2018 | 240 | 0.14 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.14 | Why? |
| Wearable Electronic Devices | 1 | 2021 | 694 | 0.13 | Why? |
| Fellowships and Scholarships | 1 | 2021 | 931 | 0.13 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Heart Rate | 1 | 2021 | 1527 | 0.11 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.10 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.10 | Why? |
| Haloperidol | 1 | 2009 | 78 | 0.09 | Why? |
| Pituitary-Adrenal System | 1 | 2009 | 135 | 0.09 | Why? |
| Neural Pathways | 1 | 2009 | 155 | 0.09 | Why? |
| Hypothalamo-Hypophyseal System | 1 | 2009 | 187 | 0.09 | Why? |
| Mood Disorders | 1 | 2011 | 431 | 0.08 | Why? |
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2008 | 184 | 0.08 | Why? |
| Psychomotor Performance | 2 | 2004 | 110 | 0.08 | Why? |
| Brain Mapping | 1 | 2008 | 228 | 0.08 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.08 | Why? |
| Carrier Proteins | 1 | 2009 | 513 | 0.08 | Why? |
| Clozapine | 1 | 2009 | 218 | 0.07 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.07 | Why? |
| Adult | 14 | 2021 | 244371 | 0.07 | Why? |
| Psychology | 1 | 2009 | 447 | 0.07 | Why? |
| Brain Chemistry | 1 | 2004 | 49 | 0.07 | Why? |
| Female | 16 | 2021 | 380317 | 0.07 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Humans | 24 | 2021 | 930598 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Reward | 1 | 2004 | 146 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| alpha-Methyltyrosine | 1 | 2002 | 3 | 0.06 | Why? |
| Diphenhydramine | 1 | 2002 | 5 | 0.06 | Why? |
| Memory Disorders | 1 | 2004 | 190 | 0.06 | Why? |
| Imaging, Three-Dimensional | 1 | 2008 | 680 | 0.06 | Why? |
| Environment | 1 | 2009 | 769 | 0.06 | Why? |
| Personality Inventory | 1 | 2002 | 72 | 0.06 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.06 | Why? |
| Male | 14 | 2021 | 367725 | 0.06 | Why? |
| Dopamine | 1 | 2002 | 123 | 0.06 | Why? |
| Norepinephrine | 1 | 2002 | 152 | 0.06 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.05 | Why? |
| Internship and Residency | 1 | 2021 | 4987 | 0.05 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Tryptophan | 1 | 2002 | 218 | 0.05 | Why? |
| Antipsychotic Agents | 1 | 2009 | 887 | 0.05 | Why? |
| Flumazenil | 1 | 2018 | 4 | 0.05 | Why? |
| Carbon Radioisotopes | 1 | 2018 | 35 | 0.05 | Why? |
| Gyrus Cinguli | 1 | 2018 | 28 | 0.05 | Why? |
| Neuropsychological Tests | 1 | 2004 | 954 | 0.05 | Why? |
| Affect | 1 | 2004 | 549 | 0.05 | Why? |
| Parietal Lobe | 1 | 2018 | 29 | 0.05 | Why? |
| Schizophrenia | 1 | 2009 | 1018 | 0.05 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.05 | Why? |
| Electronic Health Records | 2 | 2020 | 3492 | 0.04 | Why? |
| Stress, Physiological | 1 | 2021 | 378 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Morals | 1 | 2021 | 483 | 0.04 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.04 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.04 | Why? |
| Genetic Variation | 1 | 2009 | 3919 | 0.04 | Why? |
| Circadian Rhythm | 1 | 2021 | 607 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Phenotype | 1 | 2004 | 4037 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2021 | 8248 | 0.03 | Why? |
| Receptors, Neuropeptide Y | 1 | 2011 | 4 | 0.03 | Why? |
| Magnetic Resonance Imaging | 1 | 2008 | 6551 | 0.03 | Why? |
| Psychiatric Status Rating Scales | 1 | 2018 | 1340 | 0.03 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.03 | Why? |
| Double Bind Interaction | 1 | 2009 | 1 | 0.03 | Why? |
| Dysbindin | 1 | 2009 | 1 | 0.03 | Why? |
| Dystrophin-Associated Proteins | 1 | 2009 | 2 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Signal Transduction | 1 | 2004 | 7207 | 0.02 | Why? |
| Brain | 1 | 2004 | 5133 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Haplotypes | 1 | 2009 | 853 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Reaction Time | 1 | 2004 | 96 | 0.02 | Why? |
| Pattern Recognition, Visual | 1 | 2004 | 32 | 0.02 | Why? |
| Time Factors | 1 | 2008 | 31397 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Remission, Spontaneous | 1 | 2004 | 186 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Alcoholism | 1 | 2011 | 691 | 0.02 | Why? |
| Memory, Short-Term | 1 | 2004 | 137 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Animals | 2 | 2011 | 78931 | 0.02 | Why? |
| Prefrontal Cortex | 1 | 2004 | 151 | 0.02 | Why? |
| Students, Medical | 1 | 2021 | 4032 | 0.01 | Why? |
| Drug Delivery Systems | 1 | 2011 | 1365 | 0.01 | Why? |
| Attention | 1 | 2004 | 335 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2008 | 48226 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Diagnosis, Computer-Assisted | 1 | 2004 | 436 | 0.01 | Why? |
| Drug Design | 1 | 2011 | 2627 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Epilepsy | 1 | 2011 | 1401 | 0.01 | Why? |
| Cognition Disorders | 1 | 2004 | 574 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Psychometrics | 1 | 2004 | 1269 | 0.01 | Why? |
| Genotype | 1 | 2009 | 4697 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| African Americans | 1 | 2009 | 3363 | 0.01 | Why? |
| Aged | 2 | 2020 | 215776 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2004 | 17020 | 0.00 | Why? |
Charney's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(149)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(110)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_